Your browser is no longer supported. Please, upgrade your browser.
Settings
BIOS BioScrip, Inc. daily Stock Chart
BIOS [NASD]
BioScrip, Inc.
Index- P/E- EPS (ttm)-0.62 Insider Own0.50% Shs Outstand127.47M Perf Week-11.76%
Market Cap305.93M Forward P/E- EPS next Y-0.17 Insider Trans-85.51% Shs Float126.88M Perf Month-5.88%
Income-73.50M PEG- EPS next Q-0.10 Inst Own88.60% Short Float10.25% Perf Quarter-16.96%
Sales900.60M P/S0.34 EPS this Y89.80% Inst Trans1.16% Short Ratio9.32 Perf Half Y64.38%
Book/sh-0.52 P/B- EPS next Y69.10% ROA-13.50% Target Price3.88 Perf Year-20.00%
Cash/sh0.32 P/C7.55 EPS next 5Y10.00% ROE196.00% 52W Range0.98 - 3.39 Perf YTD130.77%
Dividend- P/FCF- EPS past 5Y-9.93% ROI0.00% 52W High-29.20% Beta0.26
Dividend %- Quick Ratio1.60 Sales past 5Y11.00% Gross Margin30.10% 52W Low144.90% ATR0.14
Employees2039 Current Ratio1.90 Sales Q/Q-6.20% Oper. Margin-2.00% RSI (14)34.35 Volatility5.45% 5.55%
OptionableYes Debt/Eq- EPS Q/Q-78.60% Profit Margin-9.10% Rel Volume0.62 Prev Close2.60
ShortableYes LT Debt/Eq- EarningsNov 07 BMO Payout- Avg Volume1.40M Price2.40
Recom1.50 SMA20-10.36% SMA50-14.44% SMA20010.77% Volume864,656 Change-7.69%
Aug-10-17Upgrade SunTrust Hold → Buy
Mar-06-17Reiterated Barrington Research Outperform $1.50 → $2.25
Jan-03-17Initiated Lake Street Buy $4.50
Nov-08-16Resumed Jefferies Buy
Aug-12-15Reiterated Dougherty & Company Buy $7 → $4
Aug-11-15Downgrade Sun Trust Rbsn Humphrey Buy → Neutral
Feb-04-14Reiterated Dougherty & Company Buy $8 → $12
Nov-08-13Downgrade Feltl & Co. Strong Buy → Buy $11 → $7.50
Sep-25-13Reiterated Dougherty & Company Buy $15 → $10
Jun-18-13Reiterated Dougherty & Company Buy $15 → $20
Jun-17-13Reiterated Feltl & Co. Strong Buy $17 → $20
Apr-09-13Initiated Feltl & Co. Strong Buy $15
May-10-12Reiterated Dougherty & Company Buy $10 → $13
Sep-28-11Initiated BB&T Capital Mkts Buy $10
Aug-04-09Upgrade Piper Jaffray Neutral → Overweight
Sep-12-08Downgrade Piper Jaffray Buy → Neutral
Aug-13-08Initiated Noble Financial Buy $6.50
May-06-08Reiterated Broadpoint Capital Buy $9 → $6
Apr-30-08Reiterated Dougherty & Company Buy $15 → $8
Feb-15-08Upgrade Broadpoint Capital Neutral → Buy $9
Oct-16-17 08:00AM  BioScrip to Host Third Quarter Results Call GlobeNewswire
Oct-13-17 10:33AM  ETFs with exposure to BioScrip, Inc. : October 13, 2017 Capital Cube
Oct-05-17 08:00AM  BioScrip Announces Availability of ALS Home Infusion Therapy GlobeNewswire
Oct-03-17 08:12AM  BioScrip, Inc. breached its 50 day moving average in a Bullish Manner : BIOS-US : October 3, 2017 Capital Cube
Sep-29-17 08:57AM  BioScrip, Inc. :BIOS-US: Earnings Analysis: Q2, 2017 By the Numbers : September 29, 2017 Capital Cube
Sep-13-17 01:46PM  Edited Transcript of BIOS earnings conference call or presentation 8-Aug-17 1:00pm GMT Thomson Reuters StreetEvents
Sep-12-17 08:45AM  BioScrip: Cost Cuts and Potential Legislation Sparks Analyst Coverage ACCESSWIRE
Sep-01-17 05:35AM  BioScrip's Infusion Business Strong, Dull 2017 View a Drag (Revised) Zacks
Aug-29-17 09:38PM  BioScrip, Inc. Value Analysis (NASDAQ:BIOS) : August 30, 2017 Capital Cube
Aug-23-17 09:46AM  BioScrip, Inc. breached its 50 day moving average in a Bearish Manner : BIOS-US : August 23, 2017 Capital Cube
Aug-21-17 11:07AM  BioScrip's Infusion Business Strong, Dull 2017 View a Drag Zacks
Aug-12-17 11:35PM  Edited Transcript of BIOS earnings conference call or presentation 4-May-17 1:00pm GMT Thomson Reuters StreetEvents
Aug-11-17 08:25AM  BioScrip (BIOS) Shows Strength: Stock Adds 6.6% in Session Zacks +5.19%
06:44AM  BioScrip (BIOS) Gains on CORE Initiatives, Competition Rife Zacks
Aug-09-17 09:46AM  BioScrip (BIOS) Q2 Loss Wider Than Expected, Revenues Miss Zacks
Aug-08-17 11:54PM  BioScrip reports 2Q loss Associated Press
08:00AM  BioScrip Reports Second Quarter 2017 Financial Results GlobeNewswire
06:30AM  Investor Network: BioScrip, Inc. to Host Earnings Call ACCESSWIRE
Aug-01-17 01:44PM  BioScrip, Inc. -- Moody's rates BioScrip's new debt; Caa2 CFR affirmed Moody's
Jul-27-17 08:30AM  First Choice Appoints New CFO to Help Lead Company Through Next Phase of Strategic Execution GlobeNewswire
Jul-26-17 08:00AM  BioScrip Applauds US House Passage of HR3178, the Medicare Part B Improvement Act of 2017 GlobeNewswire
Jul-17-17 09:00AM  BioScrip To Host Second Quarter Results Call GlobeNewswire
Jul-10-17 09:30AM  Zacks.com featured highlights: Ardelyx, Novavax, BioScrip, Layne Christensen and Resonant Zacks
Jul-07-17 08:41AM  5 Breakout Stocks Offering Phenomenal Returns Zacks
Jun-30-17 09:11AM  BioScrip (BIOS) Strong on Infusion, Reimbursement a Drag Zacks
Jun-29-17 08:30AM  BioScrip Announces New Senior Note Facilities GlobeNewswire -12.71%
Jun-09-17 03:41AM  Why Is BioScrip (BIOS) Up 15.3% Since the Last Earnings Report? Zacks
Jun-05-17 08:00AM  Today's Research Reports on Stocks to Watch: Synergy Pharmaceuticals and Bioscrip Inc. Accesswire
May-30-17 08:00AM  BioScrip Provides Update on UnitedHealthcare Contract GlobeNewswire
May-24-17 08:00AM  BioScrip to Present at the Jefferies 2017 Global Healthcare Conference GlobeNewswire
May-23-17 12:29PM  ETFs with exposure to BioScrip, Inc. : May 23, 2017 Capital Cube
May-11-17 04:17PM  ETFs with exposure to BioScrip, Inc. : May 11, 2017 Capital Cube
10:07AM  Dull Q1 Earnings & Tough Industry Spell Trouble for BioScrip Zacks
May-09-17 10:46AM  BioScrip, Inc. :BIOS-US: Earnings Analysis: Q1, 2017 By the Numbers : May 9, 2017 Capital Cube
May-08-17 07:41AM  Edited Transcript of BIOS earnings conference call or presentation 4-May-17 1:00pm GMT Thomson Reuters StreetEvents
May-05-17 10:47AM  BioScrip (BIOS) Q1 Loss Narrower than Expected, Sales Miss Zacks
May-04-17 09:14AM  BioScrip reports 1Q loss Associated Press
08:00AM  BioScrip Reports First Quarter 2017 Financial Results GlobeNewswire
07:40AM  Investor Network: BioScrip, Inc. to Host Earnings Call Accesswire
Apr-20-17 09:00AM  BioScrip Announces CFO Transition GlobeNewswire
Apr-17-17 09:00AM  BioScrip To Host First Quarter 2017 Results Call GlobeNewswire
Apr-03-17 07:45AM  Why Is BioScrip (BIOS) Up 18.5% Since the Last Earnings Report? Zacks -5.29%
Mar-28-17 09:29AM  BioScrip (BIOS) Stock Declines on Dull Q1 EBITDA Outlook Zacks
Mar-27-17 03:50PM  ETFs with exposure to BioScrip, Inc. : March 27, 2017 Capital Cube
03:50PM  ETFs with exposure to BioScrip, Inc. : March 27, 2017
09:01AM  BIOSCRIP, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
09:00AM  BioScrip Announces Meeting with Investors GlobeNewswire
Mar-16-17 11:32AM  BioScrip, Inc. :BIOS-US: Earnings Analysis: Q4, 2016 By the Numbers : March 16, 2017 Capital Cube
11:32AM  BioScrip, Inc. :BIOS-US: Earnings Analysis: Q4, 2016 By the Numbers : March 16, 2017
Mar-14-17 02:09PM  BioScrip, Inc. :BIOS-US: Earnings Analysis: 2016 By the Numbers : March 14, 2017
Mar-11-17 01:04PM  BIOSCRIP, INC. Financials
Mar-08-17 12:44PM  Biocon Chairman Says Stock Price Warranted on Pipeline Bloomberg Video
Mar-07-17 04:33PM  BIOSCRIP, INC. Files SEC form 10-K, Annual Report -11.45%
Mar-06-17 10:10AM  Company News for March 06, 2017 Zacks +23.37%
09:30AM  Biotech's Rally in 2017 Gaining Steam After President Trump's Speech: Today's Reports on BioScrip and Novavax Accesswire
06:43AM  BioScrip (BIOS): Q4 Loss Narrower than Expected, Sales Top Zacks
Mar-03-17 06:40PM  Edited Transcript of BIOS earnings conference call or presentation 3-Mar-17 2:00pm GMT +26.03%
09:00AM  BioScrip Inc Earnings Call scheduled for 9:00 am ET today
08:31AM  BIOSCRIP, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Other Events, Financial Statements
08:24AM  BioScrip reports 4Q loss
07:45AM  BioScrip Reports Fourth Quarter and Full-Year 2016 Financial Results GlobeNewswire
07:07AM  Q4 2016 BioScrip Inc Earnings Release - Before Market Open
Mar-02-17 04:56PM  BIOSCRIP, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered Sale of Equity Securities
04:30PM  BioScrip Raises Approximately $5 million in Private Placement of Common Stock GlobeNewswire
Feb-15-17 11:00AM  BioScrip To Host Fourth Quarter and Full-Year 2016 Results Call GlobeNewswire
Feb-06-17 04:23PM  BioScrip, Inc. Joins Coalition to Advocate for Vulnerable Medicare Patients Losing Access to Home Infusion Care Business Wire
Jan-26-17 04:03PM  BIOSCRIP, INC. Files SEC form 8-K, Change in Directors or Principal Officers
Jan-09-17 08:15AM  BIOSCRIP, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligat
Jan-06-17 02:16PM  BioScrip Announces Amendment to Credit Agreement and New Senior Loan Facility GlobeNewswire +11.85%
Jan-04-17 10:35AM  ETFs with exposure to BioScrip, Inc. : January 4, 2017 +12.23%
Jan-03-17 04:04PM  Tuesdays Monster Moves You May Have Missed +33.65%
09:20AM  Coverage initiated on Bioscrip by Lake Street
Dec-14-16 10:02AM  BIOSCRIP, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
10:00AM  BioScrip Provides Business Update and Outlines Plan to Increase Liquidity GlobeNewswire
Dec-13-16 12:30PM  ETFs with exposure to BioScrip, Inc. : December 13, 2016
Dec-07-16 06:38AM  Is Jive Software Inc (JIVE) A Good Stock To Buy? at Insider Monkey
Dec-02-16 04:26PM  BIOSCRIP, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Submission of Matters to a Vote of Secu
Dec-01-16 11:06AM  Moving Average Crossover Alert: BioScrip (BIOS)
Nov-25-16 09:01AM  Why BioScrip (BIOS) Could Be Positioned for a Slump
Nov-17-16 06:48AM  BioScrip: Guidance Disappoints, Home Solutions Raises Hope
Nov-12-16 09:46AM  4 Companies That Destroyed Shareholders Last Week at 24/7 Wall St.
Nov-10-16 12:04PM  ETFs with exposure to BioScrip, Inc. : November 10, 2016 +6.61%
Nov-09-16 02:37PM  Technically Speaking: BioScrip Inc (BIOS), Hertz Global Holdings, Inc (HTZ) And CVS Health Corp (CVS) at Insider Monkey -11.03%
11:39AM  BioScrip, Inc. :BIOS-US: Earnings Analysis: Q3, 2016 By the Numbers : November 9, 2016
Nov-08-16 10:18PM  Edited Transcript of BIOS earnings conference call or presentation 8-Nov-16 4:00pm GMT -47.89%
04:28PM  Here's Why BioScrip Inc. Imploded and Lost as Much as Half Its Value at Motley Fool
03:54PM  BioScrip Falls on Weak Earnings and Guidance
11:00AM  BioScrip Inc Earnings Call scheduled for 11:00 am ET today
07:46AM  BioScrip (BIOS): Q3 Loss Narrows Y/Y, Sales Beat Estimates
06:06AM  BIOSCRIP, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Change in Directors or Principal Of
05:00AM  BioScrip reports 3Q loss
Nov-07-16 05:00PM  BioScrip Reports Third Quarter 2016 Financial Results GlobeNewswire
07:07AM  Q3 2016 BioScrip Inc Earnings Release - After Market Close
Nov-03-16 06:06AM  BIOSCRIP, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhibits
Oct-28-16 10:01AM  BioScrip, Inc. breached its 50 day moving average in a Bearish Manner : BIOS-US : October 28, 2016
Oct-19-16 02:04PM  Daily Wrap: The Biggest Hedge Fund Moves of the Day at Insider Monkey
Oct-17-16 11:34AM  BioScrip To Host 2016 Third Quarter Results Call GlobeNewswire
Oct-08-16 09:22AM  Five Cheap Healthcare Stocks Poised to Explode at Insider Monkey
Oct-06-16 09:37AM  ETFs with exposure to BioScrip, Inc. : October 6, 2016
Oct-05-16 08:00AM  Strength Seen in BioScrip (BIOS): Stock Jumps 7.5%
BioScrip, Inc. provides home infusion services in the United States. The company engages in the preparation, delivery, administration, and clinical monitoring of pharmaceutical treatments that are administered to a patient through intravenous, subcutaneous, intramuscular, intra-spinal, and enteral methods. It is primarily involved in the intravenous administration of medications to treat a range of acute and chronic conditions, such as infections, nutritional deficiencies, immunologic and neurologic disorders, cancer, pain, and palliative care. BioScrip, Inc. offers its services at patient's homes, outpatient clinics, nursing facilities, physician's offices, and ambulatory infusion centers. The company markets and sells its products and services through sales and marketing representatives, payor relationships, and other government programs. BioScrip, Inc. was founded in 1993 and is based in Denver, Colorado.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Bronfein Michael GDirectorSep 15Sale2.6927,00072,733129,669Sep 19 03:59 PM
Coliseum Capital Management, LDirectorSep 07Sale2.881,275,6373,673,8351,888,991Sep 07 07:09 PM
Coliseum Capital Management, LDirectorSep 06Sale2.961,349,4753,994,4463,164,628Sep 07 07:09 PM
Coliseum Capital Management, LDirectorSep 05Sale3.08221,829683,2334,514,103Sep 07 07:09 PM
Coliseum Capital Management, LDirectorAug 17Sale3.05554,4761,691,1524,735,932Aug 17 07:45 PM
Coliseum Capital Management, LDirectorAug 16Sale3.11115,702359,8335,290,408Aug 17 07:45 PM
Coliseum Capital Management, LDirectorAug 15Sale3.15216,300681,3455,406,110Aug 17 07:45 PM
Kreger Jeffrey MChief Financial OfficerNov 11Buy1.3210,00013,20022,628Nov 14 11:27 AM
GREENLEAF DANIEL EChief Executive OfficerNov 10Buy1.3016,00020,78416,000Nov 14 09:06 AM
Pate R CarterDirectorNov 10Buy1.3020,00026,00084,000Nov 14 09:04 AM